U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Lixisenatide (trade name Adlyxin) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Known to be CNS penetrant in rodents. Human data not available.

Originator

Approval Year

2016
495
Targets

Targets

Primary TargetPharmacologyConditionPotency
Glucagon-like peptide 1 receptor
4
Target ID: P43220
Gene ID: 2740.0
Gene Symbol: GLP1R
Target Organism: Homo sapiens (Human)
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
ADLYXIN

Approved Use

ADLYXIN is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Launch Date

2016
PubMed

PubMed

TitleDatePubMed
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.
2010 Sep 24
Patents

Patents

WO2012156298A1
1

Sample Use Guides

In Vivo Use Guide
The starting dose of ADLYXIN is 10 mcg subcutaneously once daily for 14 days. Increase the dose to the maintenance dose of 20 mcg once daily starting on Day 15.
Route of Administration: Other
In Vitro Use Guide
Curator's Comment: In vitro, lixisenatide bound to human glucagon-like peptide-1 receptor (GLP-1R) with a greater affinity than native human GLP-1 (7-36 amide). In various in vitro and in vivo models of T2DM, lixisenatide improved glycemic measures and demonstrated promising pancreatic beta-cell-preserving actions.
Unknown
Name Type Language
LIXISENATIDE
DASH   INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
LIXISENATIDE [ORANGE BOOK]
Common Name English
LYXUMIA
Brand Name English
ZP 10
Code English
lixisenatide [INN]
Common Name English
LIXISENATIDE [USAN]
Common Name English
AVE0010
Code English
Lixisenatide [WHO-DD]
Common Name English
DES-38-PROLINE-EXENDINE-4 (HELODERMA SUSPECTUM)-(1-39)-PEPTIDYLPENTA-L-LYSYL-L-LYSINAMIDE
Common Name English
SOLIQUA 100/33 COMPONENT LIXISENATIDE
Brand Name English
LIXISENATIDE [JAN]
Common Name English
LIXISENATIDE [MI]
Common Name English
LIXISENATIDE [MART.]
Common Name English
AVE-0010
Code English
AVE 010
Code English
AVE-010
Code English
ZP-10
Code English
LIXISENATIDE COMPONENT OF SOLIQUA 100/33
Brand Name English
Classification Tree Code System Code
WHO-VATC QA10BX10
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
WHO-ATC A10BX10
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
WHO-ATC A10AE54
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
WHO-ATC A10BJ03
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
NDF-RT N0000178480
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
Code System Code Type Description
CAS
320367-13-3
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
CHEBI
85662
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
ChEMBL
CHEMBL2108336
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
RXCUI
1440051
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C166988
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
JAPANESE REVIEW
LYXUMIA
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY APPROVED JUNE 2013
IUPHAR
7387
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
WIKIPEDIA
Lixisenatide
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
DAILYMED
74O62BB01U
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
EVMPD
SUB32251
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
USAN
AB-118
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
FDA UNII
74O62BB01U
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID301029581
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
MERCK INDEX
m6875
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY Merck Index
SMS_ID
100000124357
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
LACTMED
Lixisenatide
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
DRUG BANK
DB09265
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
DRUG CENTRAL
4815
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
INN
8970
Created by admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
PRIMARY
ACTIVE MOIETY
LIXISENATIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966